Rallybio Cash Flow Statement
NASDAQ: RLYBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
15.47-0.05 (-0.32%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Rallybio free cash flow
In fiscal 2025, Rallybio generated -$29.8 million of operating cash flow. That left free cash flow of -$29.8 million, a free-cash-flow margin of -3474.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Rallybio cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -8.98M | -57.77M | -74.56M | -66.65M | -47.01M | -26.45M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 92.00K | 131.00K | 150.00K | 167.00K | 109.00K | 62.00K |
| Stock-Based Compensation | 5.31M | 7.99M | 10.92M | 9.50M | 3.65M | 704.00K |
| Change in Working Capital | -4.19M | -258.00K | 4.28M | -936.00K | -3.78M | 2.12M |
| Operating Cash Flow | -29.81M | -49.28M | -60.27M | -57.28M | -45.53M | -22.04M |
| Capital Expenditures | — | 0 | -12.00K | -54.00K | -333.00K | -137.00K |
| Investing Cash Flow | 47.27M | 33.49M | 27.66M | -112.17M | -2.33M | -2.07M |
| Financing Cash Flow | 16.00K | 5.20M | 143.00K | 51.08M | 82.97M | 144.89M |
| Net Change in Cash | 17.47M | -10.59M | -32.46M | -118.38M | 35.10M | 120.78M |
| Free Cash Flow | -29.81M | -49.28M | -60.28M | -57.34M | -45.87M | -22.18M |
This table shows 6 annual periods of Rallybio's cash flow statement, from FY 2025 back to FY 2020, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RLYB's reporting calendar. What is a cash flow statement?